Fig. 1: Decrease of ganglionic HSV loads from genital and ocular infection after meganuclease therapy.
From: Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
a, b Experimental timeline of (a) vaginal or (b) ocular infection and meganuclease therapy. RO, retroorbital; TV, tail vein. c HSV loads in DRGs from control (n = 7) and dual meganuclease-treated (n = 4) mice vaginally infected with HSV-1; p = 0.001. d. HSV loads in SCGs and TGs from control (n = 10) and dual meganuclease-treated (n = 10) mice ocularly infected with HSV-1; p = 0.0046 and 0.0034 for SCG and TG, respectively. e Gene editing at the m5 target site of residual virus quantified by T7E1 assay in SCG and TG from dual meganuclease-treated mice (n = 10). Each graph shows individual and mean values with standard deviation, percent decrease of HSV loads in treated mice compared to control mice and statistical analysis (unpaired one-tailed Mann-Whitney test with **p < 0.01). AAV loads are shown in Supplemental Fig. 9a, b. Source data are provided as a Source Data file.
